6 precise wavelengths (630, 660, 810, 830, 850 and 1060 nm) penetrate tissues to different depths to stimulate ATP production via cytochrome c oxydase.
Photobiomodulation (PBM) uses diodes emitting in the red (630-660 nm) and near-infrared (810-1060 nm). Our system leverages a multi-wavelength array covering 6 distinct wavelengths for tissue penetration at multiple levels. These wavelengths interact with cytochrome c oxydase (complex IV) of the mitochondrial respiratory chain, dissociating inhibitory nitric oxide and restoring oxygen binding.
The result: amplified ATP production, modulation of reactive oxygen species and regulation of the NF-kB pathway. Our equipment delivers a therapeutic irradiance of 130 to 150 mW/cm² depending on distance, with a target dosimetry between 4 and 10 J/cm² at the tissue (Zein, Selting & Hamblin, Journal of Biomedical Optics, 2018).
Hamblin (2017, AIMS Biophysics) demonstrated that PBM reduces inflammation through the regulation of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). Over 500 indexed scientific trials support its efficacy. Our full-body panels, targeted belts and PDT facial device allow personalized treatment of each area.
After intense effort, PBM accelerates muscle recovery and reduces DOMS (delayed onset muscle soreness). Several meta-analyses confirm a significant decrease in muscle damage markers (CK, LDH).
Osteoarthritis, tendinopathies, low back pain: PBM modulates inflammation through cytokine regulation (TNF-alpha, IL-6) and stimulates tissue regeneration, with a favorable safety profile.
Transcranial PBM improves cerebral blood flow and oxygen bioavailability in the prefrontal cortex, with measured effects on attention and working memory.
Contraindications: direct application on known malignant tumors, abdominal area during pregnancy, photosensitive epilepsy with pulsed light below 30 Hz.